title: Portal-systemic encephalopathy and gastrointestinal bleeding after cardioselective beta-blocker (metoprolol) administration to patients with portal hypertension.
abstract: The use of the non-selective beta-blocker propranolol has been widely recommended to prevent gastrointestinal bleeding in patients with portal hypertension. We conducted a prospective, randomized controlled trial of metoprolol, a selective beta-blocker for prevention of gastrointestinal bleeding from portal hypertension in 29 non-selected patients with liver disease and previous gastrointestinal bleeding. Fifteen patients received placebo treatment for 40 +/- 18 months and 14 patients received metoprolol for 31 +/- 17 months. A sustained reduction in resting pulse was observed in those patients treated with metoprolol. There was no significant difference in acute re-bleeding episodes between the two groups. Of the 14 patients treated with metoprolol, three (21%) re-bled, all three requiring blood transfusion. Four (26.5%) of the 15 patients treated with the placebo re-bled, two cases with acute bleeding and the remaining two cases presented a positive stool guaiac test. All cases who bled during the metoprolol therapy required exclusion from the trial, and surgical procedures or sclerotherapy as well. After both metoprolol or placebo treatments, similar deterioration of standard liver function tests was observed. Further, at the end of the trial, 11 patients on metoprolol (78%) and four of the patients treated with the placebo (27%) required treatment for clinical portal-systemic encephalopathy (p < 0.01). The risk of poor sympathomimetic response after cardioselective beta 1-blocker during acute bleeding episodes and the appearance of hepatic encephalopathy deserve further investigation. The selective beta-blocker metoprolol seems to be an inadequate choice to prevent gastrointestinal re-bleeding in patients with portal hypertension.
authors.affiliation: Departamento de Medicina Interna, Instituto Nacional de la Nutrición Salvador Zubirán, México, D.F.
authors.forename: M
authors.initials: M
authors.lastname: Uribe
authors.forename: H
authors.initials: H
authors.lastname: Orozco
authors.forename: S
authors.initials: S
authors.lastname: Morán
authors.forename: L
authors.initials: L
authors.lastname: Guevara
authors.forename: J L
authors.initials: JL
authors.lastname: Poo
authors.forename: F
authors.initials: F
authors.lastname: Vargas-Vorackova
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006501:Hepatic Encephalopathy / Q000139:chemically induced*; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy*; D008790:Metoprolol / Q000009:adverse effects* / Q000627:therapeutic use; D010919:Placebos; D011446:Prospective Studies
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D010919:Placebos; D008790:Metoprolol